Skip to main content
PMC home page
Springer logoLink to Springer
. 2022 Mar 8;27(4):823–824. doi: 10.1007/s10147-022-02118-8

Correction to: Osimertinib in poor performance status patients with T790M‑positive advanced non‑small‑cell lung cancer after progression of first- and second‑generation EGFR‑TKI treatments (NEJ032B)

Yukari Tsubata 1,✉, Kana Watanabe 2, Ryota Saito 3, Atsushi Nakamura 4, Hiroshige Yoshioka 5, Mami Morita 2, Ryoichi Honda 6, Nobuhiro Kanaji 7, Satoshi Oizumi 8, Daisuke Jingu 9, Taku Nakagawa 10, Kensuke Nakazawa 11, Atsuto Mouri 12, Susumu Takeuchi 13, Naoki Furuya 14, Yuki Akazawa 15, Kiyotaka Miura 16, Eiki Ichihara 17, Makoto Maemondo 18, Satoshi Morita 19, Kunihiko Kobayashi 12, Takeshi Isobe 1
PMCID: PMC9172770  PMID: 35257278

Correction to: International Journal of Clinical Oncology (2022) 27:112–120 10.1007/s10147-021-02043-2

In the original publication, the name of ninth author was mistakenly published as: Satoshi Ohizumi. The correct name is: Satoshi Oizumi as given in this Correction.

Footnotes

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Articles from International Journal of Clinical Oncology are provided here courtesy of Springer

RESOURCES